NovaBridge’s VIS-101 Delivers >10-Letter Gains and 50% Retreatment-Free Rate at Six Months
NovaBridge’s VIS-101 Phase 2a trial in 38 wet AMD patients achieved mean BCVA gains >10 ETDRS letters and median central subfield thickness reductions of 100–150 μm. Two thirds of patients were retreatment-free at four months and half at six months with no dose-limiting toxicity.
1. Phase 2a Efficacy Outcomes
VIS-101, a tetravalent dual VEGF-A/ANG-2 inhibitor, produced rapid and robust visual improvements in the randomized Phase 2a study. Patients across 3 mg and 6 mg cohorts showed mean Best Corrected Visual Acuity gains exceeding 10 ETDRS letters and median central subfield thickness reductions of 100–150 μm after three loading doses.
2. Durability and Safety Profile
The trial demonstrated potentially best-in-class durability, with approximately two thirds of participants retreatment-free at four months and half retreatment-free at six months. Safety data were favorable, with no dose-limiting toxicities and treatment-related emergent adverse events in only 8% of the higher-dose cohort.
3. Trial Design and Patient Population
The randomized study enrolled 38 patients in China aged 50–80 years, including both treatment-naïve and pre-treated individuals. Participants were assigned 2:1 to receive 6 mg (n=25) or 3 mg (n=13) doses, with baseline demographics and prior anti-VEGF exposure balanced across groups.
4. Next Development Milestones
Building on these results, NovaBridge plans a dose-determining Phase 2b study in the second half of 2026, followed by initiation of a global Phase 3 program in 2027 to further assess VIS-101’s clinical and commercial potential.